Erythromycin Topical Gel USP, 2%

Manufacturer
Bryant Ranch Prepack
Effective date
2023-08-16
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
100
Source
full-release
Hydrated at
2026-05-31 20:52:31

Label at a glance#

ProductErythromycin
Active ingredientERYTHROMYCIN
Label structure13 sections

Indications and uses

Erythromycin Topical Gel USP, 2% is indicated for the topical treatment of acne vulgaris.

Dosage and administration

Erythromycin Topical Gel USP, 2% should be applied sparingly as a thin film to affected area(s) once or twice a day after the skin is thoroughly cleansed and patted dry. If there has been no improvement after 6 to 8 weeks, or if the condition becomes worse, treatment should be discontinued, and the physician should be reconsulted. Spread the medication lightly rather than rubbing it in. There are no data directly ...

Storage and handling

Note - FLAMMABLE. Keep away from heat and flame. Store and dispense in original container. Keep tube tightly closed. Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

For Dermatologic Use Only – Not for Ophthalmic Use

Rx Only

DESCRIPTION

DESCRIPTION SECTION

Erythromycin Topical Gel USP, 2% contains erythromycin (3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*, 14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7, 12, 13-trihydroxy-3, 5, 7, 9, 11, 13-hexamethyl-6-[[3, 4, 6,-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione), for topical dermatological use. Erythromycin is a macrolide antibiotic produced from a strain of Saccaropolyspora erythraea (formerly Streptomyces erythreus). It is a base and readily forms salts with acids.

Chemically, erythromycin is C37H67NO13. It has the following structural formula:

Chemical structure
Chemical structure

Erythromycin has a molecular weight of 733.94. It is a white or slightly yellow, odorless or practically odorless, bitter crystalline powder. Erythromycin is very soluble in very polar organic solvents such as alcohols, acetone, chloroform, acetonitrile and ethyl acetate. It is moderately soluble in less polar solvents such as ether, dichloroethylene and amyl acetate. It is slightly soluble in nonpolar solvents such as hexane. It is very poorly soluble in water.

Each gram of Erythromycin Topical Gel USP, 2% contains 20 mg of erythromycin USP in a vehicle consisting of dehydrated alcohol and hydroxypropyl cellulose.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The exact mechanism by which erythromycin reduces lesions of acne vulgaris is not fully known; however, the effect appears to be due in part to the antibacterial activity of the drug.

MICROBIOLOGY

MICROBIOLOGY SECTION

Erythromycin acts by inhibition of protein synthesis in susceptible organisms by reversibly binding to 50S ribosomal subunits, thereby inhibiting translocation of aminoacyl transfer-RNA and inhibiting polypeptide synthesis. Antagonism has been demonstrated in vitro between erythromycin, lincomycin, chloramphenicol, and clindamycin.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Erythromycin Topical Gel USP, 2% is indicated for the topical treatment of acne vulgaris.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Erythromycin Topical Gel USP, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.

WARNINGS

WARNINGS SECTION

Pseudomembranous colitis has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one primary cause of “antibiotic-associated colitis”. After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against C. difficile colitis.

PRECAUTIONS

PRECAUTIONS SECTION

General -

GENERAL PRECAUTIONS SECTION

For topical use only; not for ophthalmic use. Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating or abrasive agents.

Avoid contact with eyes and all mucous membranes.

The use of antibiotic agents may be associated with the overgrowth of antibiotic-resistant organisms. If this occurs, discontinue use and take appropriate measures.

Information For Patients -

INFORMATION FOR PATIENTS SECTION

Patients using Erythromycin Topical Gel USP, 2% should receive the following information and instructions:

  1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes, nose, mouth, and all mucous membranes.
  2. This medication should not be used for any disorder other than that for which it was prescribed.
  3. Patients should not use any other topical acne medication unless otherwise directed by their physician.
  4. Patients should report to their physician any signs of local adverse reactions.

Carcinogenesis, Mutagenesis, Impairment of Fertility -

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No animal studies have been performed to evaluate carcinogenic and mutagenic potential, or effects on fertility of topical erythromycin. However, long-term (2-year) oral studies in rats with erythromycin ethylsuccinate and erythromycin base did not provide evidence of tumorigenicity. There was no apparent effect on male or female fertility in rats fed erythromycin (base) at levels up to 0.25% of diet.

Pregnancy:

PREGNANCY SECTION

Teratogenic Effects: Pregnancy Category B - There was no evidence of teratogenicity or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25% of diet) prior to and during mating, during gestation and through weaning of two successive litters. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed. Erythromycin has been reported to cross the placental barrier in humans, but fetal plasma levels are generally low.

Nursing Women -

NURSING MOTHERS SECTION

It is not known whether erythromycin is excreted in human milk after topical application. However, erythromycin is excreted in human milk following oral and parenteral erythromycin administration. Therefore, caution should be exercised when erythromycin is administered to a nursing woman.

Pediatric Use -

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

KEEP OUT OF REACH OF CHILDREN.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

In controlled clinical trials, the incidence of burning associated with erythromycin topical gel USP, 2% was approximately 25%. The following additional local adverse reactions have been reported occasionally: peeling, dryness, itching, erythema, and oiliness. Irritation of the eyes and tenderness of the skin have also been reported with the topical use of erythromycin. A generalized urticarial reaction, possibly related to the use of erythromycin, which required systemic steroid therapy has been reported.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Erythromycin Topical Gel USP, 2% should be applied sparingly as a thin film to affected area(s) once or twice a day after the skin is thoroughly cleansed and patted dry. If there has been no improvement after 6 to 8 weeks, or if the condition becomes worse, treatment should be discontinued, and the physician should be reconsulted. Spread the medication lightly rather than rubbing it in. There are no data directly comparing the safety and efficacy of b.i.d. versus q.d. dosing.

HOW SUPPLIED

HOW SUPPLIED SECTION

Erythromycin Topical Gel USP, 2% is available as follows:

30 g sealed metal tube (NDC 72162-1444-3)

60 g sealed metal tube (NDC 72162-1444-6)

STORAGE

STORAGE AND HANDLING SECTION

Note - FLAMMABLE. Keep away from heat and flame. Store and dispense in original container. Keep tube tightly closed. Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].

SPL UNCLASSIFIED SECTION

Made in Israel

Manufactured by Perrigo
Yeruham, Israel

Distributed By
Perrigo®
Allegan, MI 49010
www.perrigo.com

Rev 01-19

6J400 RC J6

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Erythromycin 2% Gel, #30

Label
Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
310152erythromycin 2 % Topical GelPSN100
310152erythromycin 0.02 MG/MG Topical GelSCD100
310152erythromycin 2 % Topical GelSY100

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
ERYTHROMYCIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
d329c2e1-5ae8-4e64-aea0-77ecea3fa1abProduct name320250717
3b331500-3b74-bd2b-fede-d46839f2f4d5Product name620240313
fdae2630-eae0-4769-abfd-8f33d5b771b4Product name320240202
8c898317-b543-1e4e-254f-84cec2f3f57eProduct name220191002
64ae94c0-3212-d73a-92da-9e6dd85c6ebeProduct name220180118
edcfa1cf-915f-1a4c-d0aa-508cc66e70d9Product name220170816
ad75fcfd-a339-42a1-9c60-43ba2c654cfaProduct name120170810
57850177-5927-151f-e1fa-7e2ca47f81e5Product name120140508
8ee71591-1d8f-e24e-242b-bfef131e3168Product name120140508
bff5cf99-0f45-fa15-2a76-b160c3c4cc3cProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
72162-1444-3Erythromycin1 in 1 CARTONGEL1100
72162-1444-3Erythromycin30 g in 1 TUBEGEL30100
72162-1444-6Erythromycin60 g in 1 TUBEGEL60100
72162-1444-6Erythromycin1 in 1 CARTONGEL1100

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
72162-1444ERYTHROMYCIN GEL [BRYANT RANCH PREPACK]100Current NDC, 4 package rows20230825_b7d11564-c92d-4eed-bdd9-8fc355e7dfc7.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
72162-1444-3GM - Gram72162-144460ff1d4d-0cb5-41a3-8834-58b0dc9cfc0c12023-09-05
72162-1444-6GM - Gram72162-14446fe203cf-7bcf-4950-a1f4-4e734aa3cc0612023-09-05
45802-966-94GM - Gram45802-9666f5b1296-774c-4381-8ae4-b947f85cabdb12012-07-24
45802-966-96GM - Gram45802-966d4cedecb-38dd-42ce-aacb-6542ae51102912012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
72162-144472162-1444-3, 72162-1444-6
45802-966

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 3 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A063211-001ERYTHROMYCINERYTHROMYCIN2%GEL / TOPICALATRS1993-01-29

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A063211-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A063211-001ERYTHROMYCIN2%GEL / TOPICALATRS1993-01-2984e616aacf4f…
2026-08-18 06:07:402026-07A063211-001ERYTHROMYCIN2%GEL / TOPICALATRS1993-01-29caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A063211-001ERYTHROMYCIN2%GEL / TOPICALATRS1993-01-29011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A063211-001ERYTHROMYCIN2%GEL / TOPICALATRS1993-01-2931067a03dcf5…
2025-08-23 18:47 UTC2025-08A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-296a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-29fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-29b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-2903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-292680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-295bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-29d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-29d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-2979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-29301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-291e350fbaab3a…
2024-05-31 18:47 UTC2024-05A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-298072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-295c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-295d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-294b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-2974a2ff9319b5…
2022-03-09 01:35 UTC2022-03A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-29bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-29782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-2987673890dc5c…
2021-03-12 10:30 UTC2021-03A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-295aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-298869cabd3fbd…
2020-11-12 02:37 UTC2020-11A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-29c0c555d07b60…
2019-12-14 00:12 UTC2019-12A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-293f01610625f2…
2019-09-15 20:21 UTC2019-09A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-29b00525d2431f…
2019-07-19 19:46 UTC2019-07A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-29ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-296a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-291c564ffb4f44…
2023-12-20 04:57 UTC2023-12A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-29ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-29a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-299b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-29a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-293f0d92c62455…
2023-05-13 08:27 UTC2023-05A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-29053a50430f4f…
2023-01-26 05:58 UTC2023-01A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-293bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-293a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A063211-001ERYTHROMYCIN2%GEL / TOPICALAT1993-01-29f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A063211-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A063211-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A063211-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A063211-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A063211-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A063211-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A063211-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A063211-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A063211-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A063211-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A063211-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A063211-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A063211-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A063211-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A063211-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A063211-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A063211-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A063211-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A063211-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A063211-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A063211-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A063211-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A063211-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A063211-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A063211-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A063211-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A063211-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A063211-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A063211-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A063211-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A063211-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A063211-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A063211-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A063211-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A063211-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A063211-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A063211-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A063211-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A063211-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A063211-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ErythromycinERYTHROMYCINBryant Ranch Prepackb7d11564-c92d-4eed-bdd9-8fc355e7dfc72023-08-16Warnings, Adverse reactionsExact identifier
ndc (package): 72162-1444-3
ndc (package): 72162-1444-6
ndc (product): 72162-1444
ndc11 (package): 72162144406
ndc11 (package): 72162144403
spl id: 04a760c9-4888-4649-8162-9767d06d8a43
spl set id: b7d11564-c92d-4eed-bdd9-8fc355e7dfc7
ErythromycinERYTHROMYCINPadagis Israel Pharmaceuticals Ltddd64459e-c88f-4ca8-b63b-fb96377a39212023-04-01Warnings, Adverse reactionsExact identifier
ndc (product): 45802-966

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.